Galera Therapeutics Management

Management criteria checks 3/4

Galera Therapeutics' El consejero delegado es J. Sorensen , nombrado en Jan 2012, tiene un mandato de 12.08 años. la remuneración anual total es $1.36M , compuesta por 43.8% salario y 56.2% primas, incluidas acciones y opciones de la empresa. posee directamente 0.61% de las acciones de la empresa, por valor de $59.44K . La antigüedad media del equipo directivo y del consejo de administración es de 3.4 años y 5.2 años respectivamente.

Key information

J. Sorensen

Chief executive officer

US$1.3m

Total compensation

CEO salary percentage	49.3%
CEO tenure	12.3yrs
CEO ownership	0.6%
Management average tenure	3.6yrs
Board average tenure	5.3yrs

Recent management updates

Recent updates

Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment

Jun 29

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Jun 15

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Mar 23

Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Feb 24

Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher

Dec 24

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Nov 04

Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

Aug 05

Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Feb 17

Galera Therapeutics EPS beats by $0.08

Nov 10

CEO Compensation Analysis

How has J. Sorensen's remuneration changed compared to Galera Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$1m	US$617k	-US$59m
Sep 30 2023	n/a	n/a	-US$70m
Jun 30 2023	n/a	n/a	-US$71m
Mar 31 2023	n/a	n/a	-US$64m
Dec 31 2022	US$1m	US$597k	-US$62m
Sep 30 2022	n/a	n/a	-US$63m
Jun 30 2022	n/a	n/a	-US$69m
Mar 31 2022	n/a	n/a	-US$77m
Dec 31 2021	US$3m	US$568k	-US$81m
Sep 30 2021	n/a	n/a	-US$84m
Jun 30 2021	n/a	n/a	-US$78m
Mar 31 2021	n/a	n/a	-US$75m
Dec 31 2020	US$3m	US$546k	-US$74m
Sep 30 2020	n/a	n/a	-US$72m
Jun 30 2020	n/a	n/a	-US$70m
Mar 31 2020	n/a	n/a	-US$65m
Dec 31 2019	US$2m	US$432k	-US$59m
Sep 30 2019	n/a	n/a	-US$52m
Jun 30 2019	n/a	n/a	-US$43m
Mar 31 2019	n/a	n/a	-US$36m
Dec 31 2018	US$522k	US$386k	-US$30m

Compensación vs. Mercado: J.($USD1.36M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD738.70K).

Compensación vs. Ingresos: La compensación de J. ha sido consistente con los resultados de la empresa en el último año.

CEO

J. Sorensen (66 yo)

12.3yrs

Tenure

US$1,250,265

Compensation

Dr. J. Mel Sorensen, M.D., serves as the Chief Executive Officer and President of Galera Therapeutics, Inc since 2012. Dr. Sorensen was the Chief Executive Officer, President, Director and Chairman of Asce...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
J. Sorensen	CEO, President & Director	12.3yrs	US$1.25m	0.61% $ 51.2k
Robert Beardsley	Co-Founder & COO	10.3yrs	US$654.09k	0.20% $ 16.7k
Christopher Degnan	Chief Financial Officer	4.5yrs	US$733.73k	0.018% $ 1.5k
Jennifer Stacey	Chief Legal & Compliance Officer and Secretary	2.5yrs	no data	no data
Andie Collier	Chief Regulatory & Quality Affairs Officer	2.7yrs	no data	no data
Judy Schnyder	Senior Vice President of Clinical Operations & Data Management	2yrs	no data	no data

3.6yrs

Average Tenure

59.5yo

Average Age

Equipo directivo experimentado: GRTXEl equipo directivo de la empresa se considera experimentado (3.3 años de antigüedad media).

Board Members

Name	Position	Tenure	Compensation	Ownership
J. Sorensen	CEO, President & Director	12.3yrs	US$1.25m	0.61% $ 51.2k
Michael Powell	Independent Chairman of the Board	7.4yrs	US$229.85k	0% $ 0
Kevin Lokay	Independent Director	5.1yrs	US$172.89k	0% $ 0
Lawrence Alleva	Independent Director	4.8yrs	US$203.91k	0.019% $ 1.6k
Emmett Cunningham	Director	5.6yrs	US$156.39k	0% $ 0
Linda West	Independent Director	4.1yrs	US$206.16k	0.11% $ 9.3k

5.3yrs

Average Tenure

66yo

Average Age

Junta con experiencia: La junta directiva de GRTX se considera experimentada (5 años de antigüedad promedio).

Galera Therapeutics Management

Management criteria checks 3/4

Key information

Recent management updates

Insufficient new directors

Insufficient new directors

CEO, President & Director recently bought US$168k worth of stock

Galera Therapeutics, Inc Appoints Eugene P. Kennedy as Chief Medical Officer

Independent Director recently bought US$55k worth of stock

Chief Medical Officer exercised options and sold US$288k worth of stock

Recent updates

New major risk - Financial position

Galera Therapeutics Receives Non-Compliance Letters from the Listing Qualifications Staff of Nasdaq

New major risk - Market cap size

New major risk - Revenue and earnings growth

Price target increased by 25% to US$0.50

Insufficient new directors

Galera Therapeutics Receives Notice from Nasdaq Regarding Listing Rule 5450(B)(2)(C)

Galera Therapeutics Receives Two Non-Compliance Notices from Nasdaq

New minor risk - Share price stability

Galera Therapeutics, Inc. Approves Reduction in the Company's Current Workforce by 22 Employees, or Approximately 70% of the Company's Headcount

Consensus revenue estimates increase by 17%

New minor risk - Market cap size

Galera Therapeutics, Inc. Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting

Insufficient new directors

Consensus revenue estimates increase by 100%

Price target decreased by 11% to US$10.00

CEO, President & Director recently bought US$168k worth of stock

Price target increased by 11% to US$12.50

Galera Therapeutics, Inc. Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis

Galera Therapeutics Receives Non-Compliance Notice from Nasdaq

Price target decreased to US$11.25

Price target increased to US$15.00

Price target increased to US$15.00

Galera Therapeutics, Inc. Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting

Galera Therapeutics (NASDAQ:GRTX) Will Have To Spend Its Cash Wisely

Galera Therapeutics, Inc Appoints Eugene P. Kennedy as Chief Medical Officer

Galera Therapeutics appoints chief medical officer

Price target increased to US$15.00

Galera Therapeutics, Inc. Announces Results from Phase 1 Stage of Greco-1 Trial of Rucosopasem with SBRT for Nsclc

Galera down ~8% after phase 1 data for non-small cell lung cancer combination treatment

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Galera Therapeutics Receives Non-Compliance Letter from Nasdaq

Galera Therapeutics, Inc. Announces Oral Presentation At 2022 American Society of Clinical Oncology Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem

Galera Announces Plan to Submit Avasopasem NDA by Year End

Galera Therapeutics, Inc. Announces Topline Results from Phase 2A Aesop Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis

Galera to Present at 2022 American Society of Clinical Oncology Annual Meeting

Price target increased to US$12.25

Is Galera Therapeutics Stock A Buy, Sell, Or Hold? Several Catalysts To Watch In 2022

Here's Why We're A Bit Worried About Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

Galera Therapeutics: Trial Reversal Did Not Take The Stock Higher

Independent Director recently bought US$55k worth of stock

Galera Therapeutics, Inc. Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem

Companies Like Galera Therapeutics (NASDAQ:GRTX) Could Be Quite Risky

Price target decreased to US$11.50

Chief Medical Officer exercised options and sold US$288k worth of stock

Will Galera Therapeutics (NASDAQ:GRTX) Spend Its Cash Wisely?

Galera Therapeutics, Inc.(NasdaqGM:GRTX) dropped from Russell 3000E Index

Independent Director recently bought US$91k worth of stock

Galera Therapeutics, Inc. Ceases Enrolling Subjects in its Phase 2 Pilot Trial of Avasopasem in Hospitalized Patients

Independent Director recently bought US$173k worth of stock

Consensus forecasts updated

Galera Therapeutics, Inc. Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer

Price target increased to US$20.75

CEO, President & Director exercised options to buy US$1.8m worth of stock.

Here's Why We're Watching Galera Therapeutics' (NASDAQ:GRTX) Cash Burn Situation

New 90-day high: US$12.39

Chief Accounting Officer exercised options and sold US$179k worth of stock

Galera Therapeutics EPS beats by $0.08

New 90-day high: US$12.81

New 90-day high: US$9.81

New 90-day low - US$6.96

Galera Therapeutics, Inc.(NasdaqGM:GRTX) dropped from Russell 3000 Value Index

Galera Therapeutics, Inc.(NasdaqGM:GRTX) dropped from Russell Microcap Value Index

CEO Compensation Analysis

CEO

Tenure

Compensation